Earnings Report 1.401 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.419 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.365 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Eli Lilly has brought in billion-dollar revenue from its weight loss drugs -- but short supply has limited the revenue opportunity. The FDA earlier this month recognized Lilly’s progress in ...

Oct 7 (Reuters) - A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s (LLY.N), opens new tab blockbuster weight loss and ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the ...

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of the impact of its blockbuster drugs for diabetes and obesity on the use ...

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...

Eli Lilly has surged 58% in 2024, driven by breakthrough weight-loss drugs and strong earnings, with shares now trading above $900. Despite valuation concerns, LLY's high growth rate and reliable ...

Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list.Yahoo Finance Senior Health Reporter Anjalee Khemlani ...